Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Is a deal/buyout in 2022 realistic?

<< Previous

Bullboard Posts

Next >>

Comment by Kswdeluxon Nov 20, 2022 2:06pm

182 Views

Post# 35113951

RE:RE:RE:Is a deal/buyout in 2022 realistic?

westcoast1000 wrote: Thanks to all for valuable comments.

KSW, the final AWARE 1 poster is available on the ONCY web site. I had thought it would address BC issues like PFS or OS, but that trial is about the tumor microenvironment so to speak. Hence its results address those kinds of issues.

If you take a look at that poster, could you interpret anything about the biomarker information and how that is demonstrated or tested for submission to regulators?

Thanks,
I was always under the understanding that AWARE-1 was set up mainly to determine biomarkers.

So I really have been expecting final data to come out and state they have confirmed the biomarkers in simple english.

ONC issued that poster with little or no duscussion. IMHO confirming biomarkers is a huge deal.

I MHO there must be more AWARE-1 data as even the latest Corporate Presentation Update shows AWARE-1 final data as Q4 2022, and is not checked off, as the completed items about are checked off. So that leads me to believe there us still more to cone.

The Corporate Presentaion was updated after the AWARE-1 poster was issued.

So confusibg for sure...